Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child.
De Rossi
A
A
Giaquinto
C
C
Del Mistro
A
A
Zamarchi
R
R
Chieco-Bianchi
L
L
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000917:Antibody Formation; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000635:transmission; D018023:HIV Seronegativity; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D019259:Lamivudine / Q000627:therapeutic use; D019888:Nelfinavir / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*; D014766:Viremia / Q000175:diagnosis / Q000276:immunology; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015483:HIV Antibodies; D019259:Lamivudine; D015215:Zidovudine; D019888:Nelfinavir